# S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

> **NCT04989985** · PHASE2 · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 302 (estimated)

## Conditions studied

- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Chemotherapy Effect

## Interventions

- **DRUG:** Oxaliplatin+S-1
- **DRUG:** Sinitilimab+oxaliplatin+S-1

## Key facts

- **NCT ID:** NCT04989985
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 302 (ESTIMATED)
- **Last updated:** 2021-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989985, "S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04989985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*